POMPILIO, G.; MORABITO, A.; CORTINOVIS, D. L.; INTEGLIA, D. Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. Global and Regional Health Technology Assessment, [S. l.], v. 9, n. 1, p. 22–29, 2022. DOI: 10.33393/grhta.2022.2351. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/2351. Acesso em: 22 jul. 2024.